Financial reports
10-K
2023 FY
Annual report
29 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
4 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
Current reports
8-K
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
18 Apr 24
8-K
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
27 Mar 24
8-K
Termination of a Material Definitive Agreement
21 Dec 23
8-K/A
Cost Associated with Exit or Disposal Activities
31 Aug 23
8-K
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
18 Jul 23
8-K
Departure of Directors or Certain Officers
13 Jul 23
8-K
Departure of Directors or Certain Officers
26 Jun 23
8-K
Results of Operations and Financial Condition
21 Jun 23
8-K
Regulation FD Disclosure
8 Jun 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 May 23
Registration and prospectus
S-8
Registration of securities for employees
10 Aug 23
424B5
Prospectus supplement for primary offering
4 Nov 22
S-8
Registration of securities for employees
4 Aug 22
S-8
Registration of securities for employees
5 Aug 21
S-3
Shelf registration
5 Aug 21
424B3
Prospectus supplement
1 Jun 21
S-3
Shelf registration
17 May 21
S-8
Registration of securities for employees
10 Aug 20
S-3
Shelf registration
4 Dec 19
D
$32M in equity / options / securities to be acquired, sold $32M, 9 investors
20 Nov 19
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
DEFA14A
Additional proxy soliciting materials
8 Jun 20
DEFA14A
Additional proxy soliciting materials
28 Apr 20
DEF 14A
Definitive proxy
28 Apr 20
DEFA14A
Additional proxy soliciting materials
18 Jun 19
Other
CT ORDER
Confidential treatment order
3 Jan 23
CT ORDER
Confidential treatment order
3 Jan 23
CT ORDER
Confidential treatment order
3 Jan 23
CT ORDER
Confidential treatment order
16 Dec 22
EFFECT
Notice of effectiveness
16 Aug 21
UPLOAD
Letter from SEC
11 Aug 21
CORRESP
Correspondence with SEC
11 Aug 21
EFFECT
Notice of effectiveness
1 Jun 21
CORRESP
Correspondence with SEC
26 May 21
UPLOAD
Letter from SEC
19 May 21
Ownership
SC 13G/A
Aquilo Capital Management, LLC
14 Feb 24
SC 13G/A
Checkpoint Capital L.P.
14 Feb 24
SC 13G/A
Lynx1 Capital Management LP
14 Feb 24
SC 13G/A
Soleus Capital Master Fund, L.P.
2 Feb 24
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
17 Aug 23
4
Ann Barbier
23 Jun 23
4
JAMES A GERAGHTY
23 Jun 23
4
Peter A Kiener
23 Jun 23
4
CHRISTOPHER P KIRITSY
23 Jun 23
4
Michael Richman
23 Jun 23